Atara BiotherapeuticsATRA -0.70%31 PS Ratio is 6.20 as of Jul. 01, 2026, which is 15% above its 10-year median of 5.39. GuruFocus rates ATRA with a GF Score™ of 31/100 and a GF Value™ of $1.56 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 934 Biotechnology companies, Atara Biotherapeutics ranks better than 60.81% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Atara Biotherapeutics's share price is $11.37.
Atara Biotherapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.84. Hence, Atara Biotherapeutics's PS Ratio for today is 6.20.
Warning Sign:
Atara Biotherapeutics Inc stock PS Ratio (=6.24) is close to 2-year high of 6.24.
The historical rank and industry rank for Atara Biotherapeutics's PS Ratio or its related term are showing as below:
ATRA'
s PS Ratio Range Over the Past 10 Years
Min: 0.25 Med: 5.39 Max: 420.96
Current: 6.2
During the past 13 years, Atara Biotherapeutics's highest PS Ratio was 420.96. The lowest was 0.25. And the median was 5.39.
ATRA's PS Ratio is ranked better than 60.81% of 934
companies
in the Biotechnology industry
Industry Median: 9.515
vs ATRA: 6.20
During the past 13 years, Atara Biotherapeutics's highest 3-Year average Revenue per Share Growth Rate was 46.90% per year. The lowest was -15.20% per year. And the median was 15.85% per year.
Back to Basics: PS Ratio
Atara Biotherapeutics (NAS:ATRA) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Atara Biotherapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atara Biotherapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Atara Biotherapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Atara Biotherapeutics's Share Price of today is $11.37. Atara Biotherapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.84.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Atara Biotherapeutics (ATRA) has a PS Ratio of 6.20 as of Jul. 01, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Atara Biotherapeutics and its competitors. This is 15% above median its historical median of 5.39. Over the past decade, Atara Biotherapeutics' PS Ratio has ranged from 0.25 to 420.96. According to the industry distribution chart, Atara Biotherapeutics ranks #366 out of 934 companies in the Biotechnology industry, placing it in the top 39.2%.
Is Atara Biotherapeutics' PS Ratio too high?
Atara Biotherapeutics' current PS Ratio of 6.20 is 15% above median its 10-year median of 5.39. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 420.96. The Biotechnology industry median PS Ratio is 9.52. Atara Biotherapeutics' value of 6.20 is 34.8% below this industry median. Based on the distribution chart, Atara Biotherapeutics ranks #366 out of 934 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Atara Biotherapeutics has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Atara Biotherapeutics' PS Ratio compare to ANIX and BMEA?
According to the Biotechnology industry distribution chart, Atara Biotherapeutics ranks #366 out of 934 companies for PS Ratio. This puts Atara Biotherapeutics in the upper half of its industry. The industry median PS Ratio is 9.52. Atara Biotherapeutics' value of 6.20 is 34.8% below this benchmark. Historically, Atara Biotherapeutics' own PS Ratio has ranged from 0.25 to 420.96 over the past decade. While the company's 10-year median is 5.39 vs. the industry median of 9.52, Atara Biotherapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.52, based on 934 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Atara Biotherapeutics's current PS Ratio of 6.20 is 34.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Atara Biotherapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atara Biotherapeutics's current PS Ratio is 6.20, which is 15% above median its own 10-year median of 5.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atara Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Atara Biotherapeutics (ATRA) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.56, compared to a current price of $11.37 — trading 628.8% above its estimated fair value. The current PS Ratio is 6.20, which is 15% above median its 10-year median of 5.39 and 34.8% below the Biotechnology industry median of 9.52. Atara Biotherapeutics' overall GF Score™ is 31/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Atara Biotherapeutics (ATRA), the current PS Ratio is 6.20 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Atara Biotherapeutics (ATRA) Overvalued in 2026?
Based on GuruFocus' analysis, Atara Biotherapeutics stock appears to be overvalued.
The current stock price of $11.37 is trading 628.8% above its estimated GF Value™ of $1.56.
GuruFocus considers Atara Biotherapeutics to be Significantly Overvalued.
Key valuation signals for ATRA:
PS Ratio: 6.20 (15% above median its 10-year median of 5.39)
GF Value™: $1.56 vs. price of $11.37 (628.8% above fair value)
Industry Position: 34.8% below the Biotechnology median (#366 of 934)
No single metric tells the full story. See the ATRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
31GF Score
Get the complete analysis for ATRA
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATRA has been successfully added to your 
